Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril-valsartan in CHF patients with Sleep Apnea
NCT02916160Phase 4Completed
- Sponsor
- CHU Montpellier
- Start
- Sep 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in chronic heart failure (CHF) and sleep apnea syndrome (SAS), sponsored by CHU Montpellier. Primary endpoint: Apnea-Hypopnea Index at 3 months. Started Sep 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)sleep apnea syndrome (SAS)
Beyond the preview
Go deeper on NCT02916160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916160.